|
| 37040466 | Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses. | Cancer Immunol Res | 2023 |
| 36215283 | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. | PLoS One | 2022 |
| 34941969 | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. | PLoS One | 2021 |
| 33023946 | Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. | Cancer Res | 2020 |
| 32017048 | Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases. | Clin Pharmacol Ther | 2020 |
| 26446943 | Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. | Clin Cancer Res | 2016 |
| 25399551 | Improved overall survival in melanoma with combined dabrafenib and trametinib. | N Engl J Med | 2015 |
| 24198242 | Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. | Clin Cancer Res | 2014 |
| 25265492 | Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. | N Engl J Med | 2014 |
| 23516391 | Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. | PLoS One | 2013 |
| 24055054 | Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. | Cell Rep | 2013 |
| 23918947 | Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. | J Clin Oncol | 2013 |
| 23833299 | Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). | Clin Cancer Res | 2013 |
| 22663011 | Improved survival with MEK inhibition in BRAF-mutated melanoma. | N Engl J Med | 2012 |
| 22967017 | Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. | BMC Cancer | 2012 |
| 23051966 | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. | Lancet Oncol | 2012 |
| 22735384 | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. | Lancet | 2012 |
| 22759480 | Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. | Lancet Oncol | 2012 |
| 21252284 | Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. | Mol Cancer Ther | 2011 |
| 21527065 | Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. | Chin J Cancer | 2011 |
| 21456017 | Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. | Cancer | 2011 |
| 21318160 | Thrombopoietin receptor levels in tumor cell lines and primary tumors. | J Oncol | 2010 |
| 19671800 | Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. | Cancer Res | 2009 |
| 18181679 | Frequent detection of androgen receptors in spindle cell lipomas: an explanation for this lesion's male predominance? | Arch Pathol Lab Med | 2008 |
| 19047115 | HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. | Clin Cancer Res | 2008 |
| 18413807 | Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. | Mol Cancer Ther | 2008 |
| 17239928 | Angiostatin receptor annexin II in vascular tumors including angiosarcoma. | Hum Pathol | 2007 |
| 17939941 | Anabolic steroids causing growth of benign tumors: androgen receptor in angiolipomas. | J Am Acad Dermatol | 2007 |
| 17635524 | Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. | Cell Prolif | 2007 |
| 17440070 | Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. | Cancer Res | 2007 |
| 16390241 | p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. | Arch Pathol Lab Med | 2006 |
| 15737031 | Giant cell tumors: inquiry into immunohistochemical expression of CD117 (c-Kit), microphthalmia transcription factor, tartrate-resistant acid phosphatase, and HAM-56. | Arch Pathol Lab Med | 2005 |
| 15169988 | Cancer of unknown primary: changing approaches. A multidisciplinary case presentation from the Joan Karnell cancer center of pennsylvania hospital. | Oncologist | 2004 |
| 15060100 | Absence of BRAF mutations in UV-protected mucosal melanomas. | J Med Genet | 2004 |
| 12676907 | Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? | J Med Genet | 2003 |
| 14566095 | Population frequencies of single nucleotide polymorphisms (SNPs) in immuno-modulatory genes. | Hum Hered | 2003 |
| 14633738 | Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. | Cancer Res | 2003 |
| 11304778 | Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. | J Clin Oncol | 2001 |
| 10978226 | Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. | Am J Hum Genet | 2000 |
| 10904085 | Genetic and hormonal risk factors in breast cancer. | J Natl Cancer Inst | 2000 |
| 10986046 | Association of HPC2/ELAC2 genotypes and prostate cancer. | Am J Hum Genet | 2000 |
| 10535446 | Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. | Diabetes | 1999 |
| 9892222 | Non-major histocompatibility complex-linked diabetes susceptibility loci on chromosomes 4 and 13 in a backcross of the DP-BB/Wor rat to the WF rat. | Diabetes | 1999 |
| 8892083 | Possible mechanism for the TCR beta-chain associated EAE resistance of LER rats. | J Neurosci Res | 1996 |
| 7541054 | Cloning of myelin basic protein-reactive T cells from the experimental allergic encephalomyelitis-resistant rat strain, LER. | J Neuroimmunol | 1995 |